INVAInnoviva, Inc.
Is it growing?
Neither accelerating nor breaking down: revenue growing +19% year on year and earnings up +1042% year on year, but operating margin narrowing (−10.8 points).
Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +4% a year.
Trailing-twelve-month earnings per share against a year earlier. Growing faster than revenue, so margins or the share count are helping.
Trailing-twelve-month operating margin, 36.9% now against 47.7% a year earlier.
All from SEC EDGAR, as of Jun 30, 2026.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.
Is INVA growing?
Innoviva, Inc. has grown revenue 15% a year over three years and 3.8% a year over five, with earnings per share compounding at 17%.
Revenue growth, 3-year annual rate · Biotechnology median +17% · steady growth, ahead of inflation · compounded from trailing twelve-month revenue
- Revenue growth, 5-year rate
- +3.8%
Revenue growth, 5-year rate · +15% over three · growth has picked up over the last three years
- Earnings per share, 3-year rate
- +17%
Earnings per share, 3-year rate · revenue +15% · earnings outgrew revenue: margins or the share count worked for shareholders
- Years of annual history on file
- 17
Years of annual history on file · FY2009 to FY2025, as filed
Details›
- Revenue FY2021
- $392M
- Revenue FY2022
- $331M
- Revenue FY2023
- $310M
- Revenue FY2024
- $359M
- Revenue FY2025
- $411M
Annual income statements as filed with the SEC.